Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) on behalf of Sonoma stockholders. Our investigation concerns whether Sonoma has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

Sonoma filed an 8-K with the SEC on November 17, 2020. The filing announced that the Company's "unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon." The Company added that the financial statements "contained material errors" and that "the Company will need to restate them."

Based on these facts, the Company's shares fell by more than 14% on the next trading day, to close at $6.82 per share on November 18, 2020.

About Bragar Eagel & Squire, P.C.:

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005891/en/